Pliant Therapeutics Stock

pliantrx.comHealthcare / BioTech & PharmaFounded: 2016Funding to Date: $187MM

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for Pliant Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Pliant Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Pliant Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Bernard Coulie MD
Chief Executive Officer, President & Board Member
Hans Hull JD
Chief Business Officer
Dean Sheppard MD
Scientific Founder and Scientific Advisor, Translational Medicine
Barbara Howes
Chief Human Resources Officer
Éric Lefebvre MD
Chief Medical Officer
Hal Chapman MD
Scientific Founder and Scientific Advisor, Translational Medicine
Keith Cummings MD
Chief Financial Officer
Rik Derynck Ph.D
Scientific Co-Founder & Scientific Advisor of Biology
William DeGrado Ph.D
Scientific Founder

Board Members

John Curnutte MD
Neil Exter
Third Rock Ventures
Hoyoung Huh Ph.D
Kevin Raidy
Cowen Group
Suzanne Bruhn Ph.D
Craig Muir
Third Rock Ventures
Smital Shah
Charles Homcy MD
Third Rock Ventures

Frequently Asked Questions About Pliant Therapeutics’ Stock

plusminus
Can you buy Pliant Therapeutics’ stock?
Pliant Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Pliant Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Pliant Therapeutics’ stock?
Yes, you can sell stock of a private company like Pliant Therapeutics. Forge can help you sell your Pliant Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Pliant Therapeutics’ stock price?
Pliant Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Pliant Therapeutics’ private market stock price with Forge Data.
plusminus
What is Pliant Therapeutics’ stock ticker symbol?
Pliant Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Novartis bets $80M on Pliant's preclinical NASH prospect
Novartis has put up $80 million to land the global license to Pliant Therapeutics’ preclinical nonalcoholic steatohepatitis (NASH) asset and three additional candidates. The NASH drug, PLN-1474, is a small molecule inhibitor of integrin αVβ1 Pliant thinks can reduce the growth of fibrotic tissue in the liver.
Updated on: Feb 28, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.